CTLA4 and melanoma: Patients with melanoma who switched from combination anti-PD-1 and anti-CTLA-4 to anti-PD-1 monotherapy reported overall irAE rates of 50%, with 18% grade ≥ 3 and 18% having the same irAE [31].